Title
Antibiotic Overuse in Premature Low Birth Weight Infants in a Developing Country
Date Issued
01 March 2019
Access level
open access
Resource Type
journal article
Publisher(s)
Lippincott Williams and Wilkins
Abstract
Background: Neonatal sepsis is a leading cause of child morbidity and mortality, especially in premature and low birth weight infants. Prompt antibiotic therapy is warranted, but its inappropriate use leads to bacterial resistance and adverse outcomes. Our objective is to describe the antibiotic use for late-onset sepsis in Peruvian premature infants. Methods: This study is a prospective study as a secondary analysis of a clinical trial in 3 neonatal care units in Peru. We included infants in the first 72 hours of life, with birth weight (BW) <2000 g. We described the antibiotic use as length of therapy (LOT) per 1000 patient days (PD) and antibiotic courses. Results: We included 408 neonates, with 12,204 PD of follow-up; 253 infants (62%) had a BW ≤1500 g. Total antibiotic use for late-onset sepsis was 2395 LOT (196 LOT/1000 PD). Two-hundred and seventy-one patients (66.4%) did not receive antibiotics for late-onset sepsis during their hospitalization. In total, 204 antibiotic courses were administered; 92 infants (22.5%) received 1 course, and 45 (11.0%) received 2-5 antibiotic courses. Mean duration of antibiotic course was 10.8 days (standard deviation: ±7.3). We found a significant association between a lower BW and increased antibiotic use per day (P < 0.001). The most commonly used antibiotics were vancomycin (143 LOT/1000 PD), carbapenems (115 LOT/1000 PD), aminoglycosides (72 LOT/1000 PD) and ampicillin (41 LOT/1000 PD). Conclusions: Premature infants receive antibiotics for longer than recommended periods of time. Antibiotic overuse is greater in neonates with lower BW. Vancomycin is the most used antibiotic. There is an urgent need to develop antimicrobial stewardship programs in our setting.
Start page
302
End page
307
Volume
38
Issue
3
Language
English
OCDE Knowledge area
Ciencias médicas, Ciencias de la salud Biología celular, Microbiología Pediatría
Scopus EID
2-s2.0-85061480709
PubMed ID
Source
Pediatric Infectious Disease Journal
ISSN of the container
08913668
Sponsor(s)
Accepted for publication March 1, 2018. From the *Universidad Peruana Cayetano Heredia, Lima, Peru; †Hospital Cay-etano Heredia, Lima, Peru; ‡Hospital Nacional Alberto Sabogal Sologuren, Lima, Peru; §Hospital Nacional Guillermo Almenara Irigoyen, Lima, Peru; and ¶University of Texas Health Science Center at Houston, Texas. Clinical Trial Registration: Lactoferrin for Prevention of Sepsis in Infants (NEO-LACTO). Registration number: NCT01525316. URL: https://clinicaltrials. gov/ct2/show/NCT01525316. Funded by the National Institute of Child Health & Human Development, grant number: R01-HD067694. Address for correspondence: Maria S. Rueda, MD, Universidad Peruana Cay-etano Heredia, Avenida Honorio Delgado 430, San Martin de Porres, Lima 31, Peru. E-mail maria.rueda@upch.pe. Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal’s website (www.pidj.com). Copyright 2018 Wolters Kluwer Health, Inc. All rights reserved. ISSN: 0891-3668/19/3803-0302 DOI: 10.1097/INF.0000000000002055
Sources of information: Directorio de Producción Científica Scopus